Lung Cancer News and Research

Latest Lung Cancer News and Research

Parents open to genetic tests for children

Genetic testing techniques have not been perfected yet but parents are willing to take the risk to know if their children are at risk for diseases in adulthood. Some parents would like the ability to predict the future, in terms of their child's risk for certain chronic health conditions. This comes in a new study published online in the journal Pediatrics. Experts, however, say the tests are of little value at this time.

19 Apr 2011

Radiology publishes Riverain Medical's SoftView chest X-ray study data in lung cancer

Riverain Medical, an industry leader and innovator in computer-aided detection and advanced visualization technologies, today announced the publication of a peer-reviewed study in Radiology demonstrating that radiologists using Riverain Medical's SoftView bone suppression application with chest X-rays significantly increased their detection of lung nodules proven to be primary lung cancer.

19 Apr 2011

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine and GVAX Prostate Cancer Vaccine BioSante Pharmaceuticals, Inc. in exchange for milestone and royalty payments after commercialization.

19 Apr 2011

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante Pharmaceuticals, Inc. today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).

19 Apr 2011

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the publication of a case report in the peer-reviewed Journal of Clinical Oncology documenting the use of tamibarotene in the successful treatment of a patient with recurrent advanced-stage acute promyelocytic leukemia.

19 Apr 2011

Bedford Labs launches cancer drug Topotecan Hydrochloride for Injection

Bedford Laboratories, a division of Ben Venue Laboratories, Inc., is pleased to announce the addition of Topotecan Hydrochloride for Injection, 4 mg (base)/vial to its diverse portfolio. Topotecan is AP Bioequivalent to the reference listed drug Hycamtin® (topotecan HCl) for injection by GlaxoSmithKline.

19 Apr 2011

Biotech Synergy concludes EP-2101 asset transfer, cancer epitopes related portfolio

Biotech Synergy has concluded the asset transfer of multi-epitope cancer vaccine product formerly known as EP-2101 and cancer epitopes related portfolio. Emile Loria, M.D., former President and Chief Business Officer of IDM and former President & CEO of Epimmune, is the founder of Biotech Synergy.

18 Apr 2011

Parents may chose predictive genetic tests for their children

Parents offered genetic testing to predict their risks of common, adult-onset health conditions say they would also test their children. That is the finding of a new study published in the May issue of Pediatrics.

18 Apr 2011

LCA-NE calls on entire delegation to show support for lung cancer community

Today, Lung Cancer Alliance-New England thanked Senator John Kerry (D-MA) for being an original sponsor of the Lung Cancer Mortality Reduction Act (S. 752), authorizing legislation that establishes a multi-agency, comprehensive research program addressing all aspects of lung cancer, and called on the entire delegation of Massachusetts to show their support for the lung cancer community.

16 Apr 2011

Proteins could lead to new therapeutic target for NF2: Wistar Institute researchers

The proteins that provide cells with a sense of personal space could lead to a therapeutic target for Neurofibromatosis Type 2, an inherited cancer disorder, according to researchers at The Wistar Institute. Their findings, which appear in the April 12 issue of the journal Cancer Cell, could have profound implications for NF2 and related cancers, such as mesothelioma.

16 Apr 2011

Scientists identify novel small molecules that block human tumor cell growth

Researchers from the Cancer Institute at NYU Langone Medical Center have identified three novel small molecules that interrupt a crucial cellular communication pathway that regulates many aspects of development and cancer.

15 Apr 2011

LCA announces additional funds for lung cancer research

Today, Lung Cancer Alliance announced that its efforts to secure increased federal research funding for lung cancer achieved another victory as an additional $12.8 million was included in the Department of Defense Congressionally Directed Medical Research Program which was part of the FY2011 budget compromise approved by Congress.

15 Apr 2011

EPO grants patent to OncoGenex OGX-427 for prostate cancer treatment

OncoGenex Pharmaceuticals, Inc., today announced that the European Patent Office has granted European Patent Number EP1545561 entitled "Oligonucleotides for Treatment of Prostate and other Cancers."

15 Apr 2011

Novelos Therapeutics acquires Cellectar

Novelos Therapeutics, Inc., a pharmaceutical company developing novel drugs for treatment and diagnosis of cancer, today announced that it has completed its acquisition of Cellectar, Inc., a Wisconsin-based drug development company, in a stock-for-stock transaction.

12 Apr 2011

Protest over planned cuts to Australian medical research funding

Australian medical researchers are protesting around the country following reports that funding to the sector could be cut in the May budget. The federal government is considering slashing $400 million from medical research.

11 Apr 2011

Scientists identify novel mechanism to control cancer spread

Saint Louis University researchers have identified a novel mechanism to control the traffic of cells and fluid from tissues to lymphatic vessels. It may be possible to harness this mechanism to fight cancer spread from one organ to another organ and improve the effectiveness of vaccines.

11 Apr 2011

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris Group announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.

8 Apr 2011

Hope4Cancer offers gentle non-invasive therapies for patients with brain tumor

Linda Roberts was puzzled when her favorite food, chocolate ice cream, suddenly did not taste good, and her prized orchids didn't smell nice either. When she began having sudden, severe headaches, she mentioned the changes in taste and smell to her doctor. After several tests, Roberts was diagnosed with a glioblastoma multiforme, the most aggressive form of brain tumor.

8 Apr 2011

Pitt, UPCI researchers' cancer studies presented at AACR meeting

How do certain multiple myeloma treatment drugs cause complications? How does the immune system become dysfunctional due to cancer? How safe is a vaccine that could prevent development of precancerous colon polyps? Those are among the many questions that will be answered by researchers from the University of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine during the American Association for Cancer Research 102nd Annual Meeting 2011, April 2 to 6, in Orlando, Fla.

7 Apr 2011

Key enzyme in non-small cell lung cancers could make standard chemotherapy more effective

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented a study at the American Association for Cancer Research's 102nd Annual Meeting 2011 that identifies a key enzyme in non-small cell lung cancers that could potentially make standard chemotherapy more effective against this highly deadly disease.

7 Apr 2011